Valbiotis SA (EPA:ALVAL)

Market Cap	26.02M +46.0%
Revenue (ttm)	905.00K +414.2%
Net Income	-9.42M
EPS	-0.47
Shares Out	23.66M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	143,629
Open	1.102
Previous Close	1.100
Day's Range	1.100 - 1.156
52-Week Range	0.535 - 1.296
Beta	-0.25
Analysts	Strong Buy
Price Target	2.50 (+124.42%)
Earnings Date	Jun 26, 2026

About Valbiotis

Valbiotis SA engages in the research and development of dietary supplements to prevent metabolic and cardiovascular diseases in France and Asia. The company offers supplements for immunity and vitality, health and wellbeing, metabolic and cardiovascular health, and beauty and physical comfort. It also develops TOTUM-63 for the reduction of fasting blood glucose and treatment of type 2 diabetes; TOTUM-854, which is in Phase II/III clinical trials for reducing systolic blood pressure; and TOTUM-448 for the reduction of hepatic steatosis. Addition...

• Industry: Packaged Foods
• Sector: Consumer Staples
• Founded: 2014
• Employees: 50
• Stock Exchange: Euronext Paris
• Ticker Symbol: ALVAL

Financial Performance

In 2025, Valbiotis's revenue was 905,000, an increase of 414.20% compared to the previous year's 176,000. Losses were -9.42 million, -6.06% less than in 2024.